Vision Disorders
Recent clinical, regulatory, research and industry developments relating to this disease.
Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia.
Adalimumab in Patients with Active Noninfectious Uveitis.
Persistence of Ebola Virus in Ocular Fluid during Convalescence.
Reactive oxygen species: from health to disease.
Approval: Ozurdex (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 clinical trial expected to report results, the earliest in Q3 2028.
Clinical MilestonesViewHide
- 2026-07-09ClinicalA Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A GeneResults expected Q3 2028
- 2026-06-01ClinicalRANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED STUDY OF THE SAFETY AND EFFICACY OF POS (0.75% PHENTOLAMINE OPHTHALMIC SOLUTION) IN PARTICIPANTS WITH PREVIOUS KERATOREFRACTIVE SURGERY WITH DECREASED VISUAL ACUITY UNDER MESOPIC CONDITIONSPrimary completion
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Cataract1
- Dementia1
- Glaucoma1
- Glaucoma, Open-Angle1
- Global Burden of Disease1
- Global Health1
- NADPH Oxidases1
- Visual Acuity1
Leading journals6
- Lancet (London, England)2
- The New England journal of medicine2
- Archives of ophthalmology (Chicago, Ill. : 1960)1
- European journal of endocrinology1
- JAMA network open1
- Swiss medical weekly1
Leading researchers8
- Andrews SJ1
- Aung T1
- Baldeschi L1
- Barisani-Asenbauer T1
- Bartalena L1
- Bourne RR1
- Brenowitz WD1
- Brézin AP1
Affiliations (unnormalised)6
- Amsterdam University Medical Center1
- and the Department of Pathology and Laboratory Medicine (C.S.K.)1
- Anglia Ruskin University1
- Boston University1
- Cardiff University School of Medicine1
- Clinic for Ophthalmology1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Vision disorders are visual impairments that limit one or more basic functions of the eye, including visual acuity, dark adaptation, color vision, or peripheral vision. They can arise from diseases of the eye, optic nerve, visual pathway, occipital lobe, ocular motility, and other conditions.
The supplied material indicates that vision disorders can result from a range of underlying diseases affecting the eye, optic nerve, visual pathway, occipital lobe, or ocular motility. It also notes that many causes of vision impairment are preventable or treatable, including cataract and undercorrected refractive error as avoidable causes.
The biological basis is impairment of visual function, reflected in reduced visual acuity, dark adaptation, color vision, or peripheral vision. In the co-studied glaucoma literature, vision loss is linked to progressive retinal ganglion cell loss, cupping of the optic nerve head, and visual-field damage, with intraocular pressure as a key modifiable factor.
The grounding does not support a single unified risk-factor profile for vision disorders overall. For glaucoma-related vision loss, risk factors include older age, elevated intraocular pressure, sub-Saharan African ethnic origin, positive family history, high myopia, hyperopia, and east Asian ethnic origin depending on glaucoma subtype. For Graves' orbitopathy, risk factors include smoking, thyroid dysfunction, high serum thyrotropin receptor antibodies, radioactive iodine treatment, and hypercholesterolemia.
Treatment depends on the underlying cause and disease subtype rather than on vision disorders as a single entity. For glaucoma, lowering intraocular pressure is the main disease-modifying approach, using laser treatments, topical medications, and surgery. For Graves' orbitopathy, management includes control of risk factors, local treatments, selenium in selenium-deficient areas, antithyroid drugs for associated Graves' hyperthyroidism, and intravenous glucocorticoids for active moderate-to-severe disease.
AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Visual impairments limiting one or more of the basic functions of the eye: visual acuity, dark adaptation, color vision, or peripheral vision. These may result from EYE DISEASES; OPTIC NERVE DISEASES; VISUAL PATHWAY diseases; OCCIPITAL LOBE diseases; OCULAR MOTILITY DISORDERS; and other conditions (From Newell, Ophthalmology: Principles and Concepts, 7th ed, p132).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.